Your browser doesn't support javascript.
loading
Triptan use in Italy: Insights from administrative databases.
Da Cas, Roberto; Nigro, Anna; Terrazzino, Salvatore; Sances, Grazia; Viana, Michele; Tassorelli, Cristina; Nappi, Giuseppe; Cargnin, Sarah; Pisterna, Alessia; Traversa, Giuseppe; Genazzani, Armando A.
Afiliação
  • Da Cas R; National Centre for Epidemiology, Surveillance and Health Promotion, National Institute of Health, Italy.
  • Nigro A; S.C. Farmaceutica Territoriale, Italy.
  • Terrazzino S; Department of Pharmaceutical Sciences, ''A. Avogadro'' University, Italy.
  • Sances G; Headache Science Center - C. Mondino National Neurological Institute, Italy.
  • Viana M; Headache Science Center - C. Mondino National Neurological Institute, Italy.
  • Tassorelli C; Headache Science Center - C. Mondino National Neurological Institute, Italy; Department of Brain and Behavioral Sciences, University of Pavia, Italy.
  • Nappi G; Headache Science Center - C. Mondino National Neurological Institute, Italy.
  • Cargnin S; Department of Pharmaceutical Sciences, ''A. Avogadro'' University, Italy.
  • Pisterna A; S.C. Farmaceutica Territoriale, Italy.
  • Traversa G; National Centre for Epidemiology, Surveillance and Health Promotion, National Institute of Health, Italy.
  • Genazzani AA; Department of Pharmaceutical Sciences, ''A. Avogadro'' University, Italy armando.genazzani@pharm.unipmn.it.
Cephalalgia ; 35(7): 619-26, 2015 Jun.
Article em En | MEDLINE | ID: mdl-25246521
ABSTRACT

INTRODUCTION:

In this drug utilization study, we aimed at assessing the pattern of triptan use in Italy by means of the drug prescription databases of two local health authorities, accounting for approximately 1 million citizens.

METHODS:

The study population included all residents aged 18 to 84 years in the Vercelli province (about 175,000 inhabitants) and in the Umbria region (about 885,000 inhabitants), who had at least one dispensation for triptans in 2012. A frequent user, who might be at risk of medication-overuse headache (MOH), was defined as a patient being dispensed at least 10 defined daily doses (DDD) of triptans every month for at least three consecutive months.

RESULTS:

Triptans were used by 0.7%-1% of the population. While most patients were dispensed fewer than 60 DDDs per year, about 10% of all triptan users were classified as frequent users. In both areas, patients below the age of 29 were less likely to be frequent users while the 40- to 49-year-old population was the most affected, with no sex difference. About two-thirds of frequent users persisted in this behavior for an additional three-month period in the following six months.

CONCLUSIONS:

Our data indicate that approximately 10% of all triptan users in the Italian population are potentially at risk for MOH. An approach based on drug prescription databases could be useful to identify patients at risk for MOH.
Assuntos
Palavras-chave

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Triptaminas / Bases de Dados Factuais / Uso de Medicamentos / Transtornos da Cefaleia Secundários / Transtornos de Enxaqueca Tipo de estudo: Diagnostic_studies / Prognostic_studies Limite: Adolescent / Adult / Aged / Aged80 / Female / Humans / Male / Middle aged País/Região como assunto: Europa Idioma: En Revista: Cephalalgia Ano de publicação: 2015 Tipo de documento: Article País de afiliação: Itália

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Triptaminas / Bases de Dados Factuais / Uso de Medicamentos / Transtornos da Cefaleia Secundários / Transtornos de Enxaqueca Tipo de estudo: Diagnostic_studies / Prognostic_studies Limite: Adolescent / Adult / Aged / Aged80 / Female / Humans / Male / Middle aged País/Região como assunto: Europa Idioma: En Revista: Cephalalgia Ano de publicação: 2015 Tipo de documento: Article País de afiliação: Itália